BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

View Clinical Trials from BioPharm Insight


Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.




 Key Statistics


Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics (CA)
Employees: 429
Symbol: NKTR
 









 Company News
Nektar Therapeutics (CA) (NKTR) Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-Deficient Cancer Model 11/20/2014 10:09:11 AM
Nektar Therapeutics (CA) (NKTR) Reports Financial Results For The Third Quarter Of 2014 11/7/2014 8:06:42 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets 10/30/2014 9:39:02 AM
Nektar Therapeutics (CA) (NKTR) Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation 9/26/2014 8:36:48 AM
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting 9/19/2014 8:10:52 AM
FDA Approves AstraZeneca PLC (AZN), Nektar Therapeutics (CA) (NKTR)'s MOVANTIK™ For Opioid-Induced Constipation 9/16/2014 12:45:25 PM
Nektar Therapeutics (CA) (NKTR) Reports Financial Results For The Second Quarter Of 2014 8/1/2014 7:00:01 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets 7/23/2014 12:17:04 PM
Nektar Therapeutics (CA) (NKTR) Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists 6/11/2014 9:42:15 AM
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data For NKTR-214, A Novel Cancer Immunotherapy, At 50th American Society of Clinical Oncology Meeting 6/2/2014 6:46:36 AM
12345678910...